BRAINTREE, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Haemonetics Corporation CEO, Brad Nutter, will be presenting at the UBS Life Sciences Conference on Wednesday, September 26, 2007 at 2:30 pm. Mr. Nutter's presentation will be webcast live at http://www.ibb.ubs.com. The webcast will be available for replay through October 27, 2007 at the same URL address.
During the presentation, Mr. Nutter will give an overview of Haemonetics' investment thesis, including a review of the Company's product line revenue growth drivers. These are plasma consumables, which are expected to grow 10-13% annually; red cell consumables which are expected to grow about 10% annually; OrthoPAT consumables, which are expected to grow 10-15% annually, and software and services which is expected to grow 18-22% annually.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.
CONTACT: Julie Fallon
Tel. (781) 356-9517
Alternate Tel. (617) 320-2401
|SOURCE Haemonetics Corporation|
Copyright©2007 PR Newswire.
All rights reserved